

## For an Encouraging Year Ahead

EDITORIAL

Endocrinol Res Pract. 2024;28(1):1

Dear Readers,

After the pandemic, we are leaving behind a year filled with serious problems for our country and all of humanity, such as senseless and seemingly endless wars, economic crises, earthquakes, and global warming. Welcoming the year 2024, let us hope it is not as challenging as the past year. As I convey my wishes for logic, peace, and prosperity in the new year to our readers and all of humanity, I would like to share some statistics for our journal with you.

Last year, our journal evaluated 119 articles, of which 36.1% were accepted. Out of the 63.9% that were rejected, 16.8% were before peer review, and 59.1% were after evaluation. Looking at the evaluation periods, the time to the first decision during this period has decreased to 38.6 days, the time from the first submission to the final decision is 63.8 days, and the average time to publication after acceptance is two months. Considering our journal is published quarterly, in 2024, we plan to decline this to around three weeks by increasing the online 'print aheads' after acceptance.

As the entire editorial team, our goal is to capture more valuable, original, and interesting publications, making them as perfect as possible through high-quality and detailed peer reviews, recommendations from associate editors, and necessary English syntax corrections as needed. We also aim to make them visible and accessible on the international stage as soon as possible. We are inviting distinguished and well-known authors from our community to write review articles, aiming to provide our readers with exclusive, valuable, and practical information. In this context, in the first issue of 2024, we feature a review by an internationally renowned Turkish surgeon, Cumhuri Arıcı, along with Mehmet İlker Turan, summarizing the current approach to primary hyperparathyroidism. Additionally, we have a large multicenter study evaluating the effectiveness and safety of initiating insulin glargine 300 U/mL in insulin-naïve patients, uncontrolled on oral antidiabetics (The EASE Study).

Reminding once again that scientific journals cannot exist without reviewers, I would like to express our gratitude to all the reviewers, listed on "Reviewer Acknowledgement", who contributed to our journal and dedicated their worthy time to evaluations in 2023. I would also like to extend my thankfulness to our deputy editor, Dilek Gogas Yavuz, Associate editors Neslihan Başçıl Tütüncü, Canan Ersoy, and Fatih Tanrıverdi, for their devoted job.

May 2024 bring pleasant days to our country and the world.

Wishing our readers the best for the new year!

Murat Faik Erdoğan

Editor-in-Chief

Publication Date: January 2, 2024

DOI: 10.5152/erp.2024.24001



Copyright © Author(s) – Available online at <http://endocrinolrespract.org>  
This journal is licensed under a Creative Commons (CC BY-NC-SA) 4.0 International License.